Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer. - Wikidata - awgldk - TriplyDB

Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer.

Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer.

http://www.wikidata.org/entity/Q33396506

about

The Phase 2 Study of "(TOX) Preoperative Chemotherapy" Response Rate and Side Effects in [Locally Advanced Operable Gastric Adenocarcinoma] Patients With Docetaxel, Oxaliplatin and Capcitabine Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers 5-Fluorouracil derivatives: a patent review.Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.In vitro synergistic action of geldanamycin- and docetaxel-containing HPMA copolymer-RGDfK conjugates against ovarian cancer Helicobacter pylori: gastric cancer and extragastric intestinal malignancies.Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.Seven-day capecitabine plus docetaxel and oxaliplatin regimen for the treatment of advanced gastric cancer: A phase-I clinical trial.Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer.Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study.Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.Complete Pathological Response in a Patient with Metastatic Esophageal Cancer Treated with a Regimen of Capecitabine, Oxaliplatin and Docetaxel: A Case Report

P2860

Q34082404-5B35B0E0-9D3B-4588-95B6-3300375D72AF Q34214957-D8ED21B5-D857-4884-8944-041B1148E617 Q34253978-B270473C-D699-4D5A-AA86-94C492B18B50 Q34658209-9128DF2D-2F95-4FB4-A43D-D64C06A79366 Q34674722-E834C9D2-CB14-4F0C-B700-1E12EC7056FC Q38041643-1D1C1E39-412D-4E13-83D2-24274AF7AD02 Q38420500-3B94A8B1-4CC8-4FB5-97A5-B6DE95E577ED Q38729844-B46DC990-4014-4C79-BDFF-A0A559BBE46F Q40914919-0D9E2DFC-B855-4ED5-B423-BC74D770E9BA Q41187621-E873E8E2-885C-4395-A972-598A26A868F3 Q44136997-3ACE3748-F4D7-40D5-A4E4-2C3CBB7805D2 Q53252056-AA5900BF-C646-4BDB-926C-085C50D96B76 Q57385800-105D4E9D-8BC5-40D3-9A85-C482A6F6E261

P2860

Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer.

http://www.wikidata.org/entity/Q33396506

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Docetaxel plus oxaliplatin in ...... t for advanced gastric cancer.

@ast

Docetaxel plus oxaliplatin in ...... t for advanced gastric cancer.

@en

type

label

Docetaxel plus oxaliplatin in ...... t for advanced gastric cancer.

@ast

Docetaxel plus oxaliplatin in ...... t for advanced gastric cancer.

@en

prefLabel

Docetaxel plus oxaliplatin in ...... t for advanced gastric cancer.

@ast

Docetaxel plus oxaliplatin in ...... t for advanced gastric cancer.

@en

P1433

Q33396506-A68E3D53-1D40-4B8C-8DD9-DF67600C99A9

P1476

Q33396506-E1555CAC-6B5C-4F2F-B13C-52BA4DE4D519

P2093

Q33396506-15A734EC-F1E3-4870-BFD0-412035F99F8C

Q33396506-1E31BB02-5FF0-4E71-A7E3-F7ABA816F4AD

Q33396506-262DE23D-A4D8-4083-AFE8-058C1FD0128B

Q33396506-3F6A844A-6A10-4281-9172-00E0EE0FAF07

Q33396506-3FE1B909-32B6-4421-89B9-73CFE83CB2E2

Q33396506-6FF6975A-52DC-48DD-B855-E256B29AABD6

Q33396506-85408F42-52D5-4DBB-BC76-50C849908AD8

Q33396506-C21C1B94-14BB-4474-AAFA-E73A3E67CDAF

Q33396506-C79FBBDF-BCC0-40BF-B225-D8D7FF3C3E01

Q33396506-EA3922C1-7C8A-4DC3-917C-C7124110157B

P2860

Q33396506-20365BE0-69E3-43F9-AE7B-1FC278FF5851

Q33396506-379F19DE-2AB8-4A08-9D4A-CF9C2274FD39

Q33396506-478B0AC8-4348-40D5-99F9-15A8F71C2D70

Q33396506-49C45845-CFE8-48E2-B428-BEB073759135

Q33396506-4A4D2ACB-9BB3-49AA-8F11-34A94F7F203A

Q33396506-4A8E1E01-6C1C-4170-A126-4F7D9D7C381B

Q33396506-69601205-E768-46EE-BE0A-1D320C51AB56

Q33396506-7DD6D1B9-252D-438A-883C-437C12D8D239

Q33396506-8D7BE44F-EA9B-4845-B91C-79B02E727C7F

Q33396506-AAB415C6-A1F8-4969-B6A0-0B8CD2C27693

P304

Q33396506-ABE2615C-062C-41A1-B202-274A86B6B6DD

P31

Q33396506-CB58866C-22A9-4E25-A184-5FEE757C220D

P356

Q33396506-5178200D-3283-42E9-B3EC-41AB0C252E09

P433

Q33396506-D4D1D133-015B-4219-B343-0434176405A0

P478

Q33396506-A8F0C1AB-F2C1-4080-8034-4084C7D83871

P577

Q33396506-03F80151-76BB-4B73-952E-CEE7C943D2AA

P5875

Q33396506-D97FB5F6-D65A-4960-B390-58B19B603C38

P698

Q33396506-2D64F93A-AE89-4DC8-87FF-BD687AFF7B85

P356

P1433

P1476

Docetaxel plus oxaliplatin in ...... t for advanced gastric cancer.

@en

P2093

A Karayiannakis

http://www.w3.org/2001/XMLSchema#string

A Tentes

http://www.w3.org/2001/XMLSchema#string

E Chamalidou

http://www.w3.org/2001/XMLSchema#string

K Amarantidis

http://www.w3.org/2001/XMLSchema#string

L Chelis

http://www.w3.org/2001/XMLSchema#string

M Karanikas

http://www.w3.org/2001/XMLSchema#string

N Xenidis

http://www.w3.org/2001/XMLSchema#string

P Dimopoulos

http://www.w3.org/2001/XMLSchema#string

P Michailidis

http://www.w3.org/2001/XMLSchema#string

S Deftereos

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics, 2002

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer.

A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors.

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer.

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.

P304

359-365

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000330199

http://www.w3.org/2001/XMLSchema#string

P433

5-6

http://www.w3.org/2001/XMLSchema#string

P478

80

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51542071

http://www.w3.org/2001/XMLSchema#string

P698

21811088

http://www.w3.org/2001/XMLSchema#string